BRAIN & DEVELOPMENT, vol.42, no.5, pp.418-420, 2020 (SCI-Expanded)
We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels.